9 years of revenue, profit, cash flow and balance-sheet history through FY2025,
from SEC filings — with a computed, factual read of the trend.
Updated Overview →
Growth & profitability
Revenue has grown 25.9% per year over the past 5 years.
Operating margin has expanded, at -2581.6% in the latest year.
Financial health
Total debt ($3M) exceeds cash ($88000); net debt is $3M.
The company is unprofitable and has less than a year of cash runway at its current free-cash-flow burn.
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Free cash flow (CFO − capex)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key annual figures
FY
Revenue
Net income
Gross M
Op M
FCF
Total debt
Cash
2025
$819000
-$17M
92.3%
-2581.6%
-$8M
$3M
$88000
2024
$420000
-$17M
90.0%
-2676.9%
-$9M
—
$3M
2023
$442000
-$71M
93.2%
-17674.0%
-$21M
—
$4M
2022
$14000
-$27M
-1050.0%
-192578.6%
-$23M
—
$16M
2021
$22000
-$25M
-6990.9%
-133027.3%
-$28M
—
$15M
2020
$259000
-$36M
-738.6%
-13668.3%
-$28M
—
$24M
2019
$7M
-$57M
-22.9%
-801.9%
-$33M
$558000
$15M
2018
$6M
-$31M
32.8%
-498.0%
-$19M
$850000
$64M
2017
$6M
-$18M
29.0%
-302.6%
-$6M
—
$8M
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Free cash flow (CFO − capex, quarterly)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key quarterly figures
Quarter
Revenue
Net income
Gross M
Op M
FCF
Total debt
Cash
Mar '26
$432000
-$2M
90.3%
-536.6%
-$3M
—
$441000
Dec '25
$238000
-$6M
91.6%
-4143.3%
-$2M
$3M
$88000
Sep '25
$226000
-$2M
92.0%
-1336.7%
-$2M
$2M
$1M
Jun '25
$212000
-$5M
93.4%
-2210.4%
-$2M
$2M
$838000
Mar '25
$143000
-$4M
92.3%
-2500.0%
-$2M
—
$450000
Dec '24
$149000
-$6M
92.6%
-2047.7%
-$3M
—
$3M
Sep '24
$96000
-$4M
89.6%
-2978.1%
-$3M
—
$1M
Jun '24
$93000
-$4M
82.8%
-2921.5%
-$2M
—
$16000
Mar '24
$82000
-$3M
93.9%
-3190.2%
-$2M
—
$1M
Dec '23
—
-$669000
—
—
-$2M
—
$4M
Sep '23
—
-$2M
—
—
-$2M
—
$6M
Jun '23
—
-$2M
—
—
-$5M
—
$7M
Mar '23
$85000
-$66M
88.2%
-78216.5%
-$12M
—
$12M
Dec '22
$0
-$8M
—
—
-$3M
—
$16M
Sep '22
$0
-$5M
—
—
-$5M
—
$14M
Jun '22
$5000
-$8M
-1220.0%
-169200.0%
-$6M
—
$11M
Mar '22
$9000
-$5M
-955.6%
-61144.4%
-$9M
—
$18M
Dec '21
$5000
-$8M
-6840.0%
-165280.0%
-$6M
—
$15M
Sep '21
$5000
-$4M
-4820.0%
-147880.0%
-$7M
—
$21M
Jun '21
$9000
-$5M
-5677.8%
-74866.7%
-$7M
—
$20M
Valuation over time
How the market has priced VTAK against its own fundamentals since 2023-08 —
each month-end's share price set against the most recent annual filing, so the multiple moves
as price runs ahead of (or behind) earnings. Split-adjusted.
The price-to-sales ratio has fallen from 103.9× (Aug '23) to 3.5× (Jun '26).
Price / sales (P/S)
P/S
Frequently asked questions
Is VTAK growing its revenue and profit?
Over the past 5 years, Catheter Precision, Inc.'s revenue has grown 25.9% per year. These are computed facts, not advice.
How much debt does VTAK have?
As of FY2025, Catheter Precision, Inc. reported $3M of total debt against $88000 of cash.
What is VTAK's profit margin?
In FY2025, gross margin was 92.3%, operating margin -2581.6%, and net margin -2098.0%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted ·
growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price
against the latest annual filing. Informational only — not investment advice.